JP Morgan 2024 | Endpoints panel
Creating ROI from AI
Learn about the importance of discovering new biology and the role of AI in augmenting drug discovery and development.
During the JPM Healthcare Conference 2024, Endpoints hosted a panel 'Creating ROI from AI' with panelists Thomas Clozel, Co-founder and CEO, Owkin; Venkat Sethuraman, Global Head of Biometrics and Data Sciences, BMS; Matthias Evers, Chief Business Officer, Evotec; Frank Nestle, Head of Research and Chief Scientific Officer, Sanofi.
Video chapters
00:00-01:03
Intro
01:06-04:30
What is driving the ROI in BMS’ AI strategy?
04:30-06:44
What is driving the ROI in Sanofi’s AI strategy?
06:44-08:40
What is driving the ROI in Owkin’s AI strategy?
08:40-10:30
What is driving the ROI in Evotec’s AI strategy?
10:30-12:00
Algorithms aren’t a commodity, but data is
12:00-14:06
Navigating a 3-dimensional space to use AI well in drug discovery
14:07-16:00
The differentiator is high quality multidimensional molecular data
16:00-21:47
What are some of the skills and jobs that AI will replace?
21:47-24:44
What are the top misleading AI claims?
24:44-29:00
The problem all drug discoverers face